Venus Medtech (Hangzhou)
Market Cap
HK$38.3b
Last Updated
2021/01/23 10:23 UTC
Data Sources
Company Financials +
Executive Summary
Venus Medtech (Hangzhou) Inc. develops and sells transcatheter heart valve medical devices in Mainland China and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Exceptional growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Venus Medtech (Hangzhou)'s share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2500 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 2500's weekly volatility (9%) has been stable over the past year.
Market Performance
7 Day Return
27.9%
2500
10.9%
HK Medical Equipment
3.5%
HK Market
1 Year Return
109.8%
2500
113.9%
HK Medical Equipment
15.1%
HK Market
Return vs Industry: 2500 underperformed the Hong Kong Medical Equipment industry which returned 113.9% over the past year.
Return vs Market: 2500 exceeded the Hong Kong Market which returned 15.1% over the past year.
Shareholder returns
| 2500 | Industry | Market | |
|---|---|---|---|
| 7 Day | 27.9% | 10.9% | 3.5% |
| 30 Day | 17.7% | 12.5% | 12.7% |
| 90 Day | 26.2% | 20.7% | 18.1% |
| 1 Year | 109.8%109.8% | 117.3%113.9% | 19.7%15.1% |
| 3 Year | n/a | 223.3%207.7% | -5.1%-15.1% |
| 5 Year | n/a | 353.3%314.9% | 65.1%37.0% |
Long-Term Price Volatility Vs. Market
How volatile is Venus Medtech (Hangzhou)'s share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner3 weeks ago | Simply Wall St
Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?3 weeks ago | Simply Wall St
Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?Valuation
Is Venus Medtech (Hangzhou) undervalued compared to its fair value and its price relative to the market?
10.21x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 2500 (HK$90.65) is trading above our estimate of fair value (HK$55.13)
Significantly Below Fair Value: 2500 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 2500 is unprofitable, so we can't compare its PE Ratio to the HK Medical Equipment industry average.
PE vs Market: 2500 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2500's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2500 is overvalued based on its PB Ratio (10.2x) compared to the HK Medical Equipment industry average (3.9x).
Next Steps
Future Growth
How is Venus Medtech (Hangzhou) forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
50.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2500 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: 2500 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 2500's is expected to become profitable in the next 3 years.
Revenue vs Market: 2500's revenue (46.7% per year) is forecast to grow faster than the Hong Kong market (14.4% per year).
High Growth Revenue: 2500's revenue (46.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2500's Return on Equity is forecast to be high in 3 years time (22.2%)
Next Steps
Past Performance
How has Venus Medtech (Hangzhou) performed over the past 5 years?
30.0%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 2500 is currently unprofitable.
Growing Profit Margin: 2500 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2500's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2500's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2500 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.7%).
Return on Equity
High ROE: 2500 has a negative Return on Equity (-7.92%), as it is currently unprofitable.
Next Steps
Financial Health
How is Venus Medtech (Hangzhou)'s financial position?
Financial Position Analysis
Short Term Liabilities: 2500's short term assets (CN¥2.6B) exceed its short term liabilities (CN¥415.5M).
Long Term Liabilities: 2500's short term assets (CN¥2.6B) exceed its long term liabilities (CN¥58.4M).
Debt to Equity History and Analysis
Debt Level: 2500's debt to equity ratio (0.03%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 2500's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2500 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2500 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Venus Medtech (Hangzhou) current dividend yield, its reliability and sustainability?
0.007%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2500's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2500's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2500's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2500's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2500's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.5yrs
Average management tenure
CEO
Venus Medtech (Hangzhou) has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 2.17yrs | no data | 11.34% CN¥ 4.3b | |
| CFO & Joint Company Secretary | 1.5yrs | no data | no data | |
| COO, CTO & Executive Director | 2.17yrs | no data | 1.09% CN¥ 416.4m | |
| GM & Executive Director | 8.17yrs | no data | 9.93% CN¥ 3.8b | |
| Head of U.S. Operations | 1.5yrs | no data | no data | |
| Joint Company Secretary | no data | no data | no data |
1.5yrs
Average Tenure
50yo
Average Age
Experienced Management: 2500's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 2.17yrs | no data | 11.34% CN¥ 4.3b | |
| COO, CTO & Executive Director | 2.17yrs | no data | 1.09% CN¥ 416.4m | |
| GM & Executive Director | 8.17yrs | no data | 9.93% CN¥ 3.8b | |
| Vice-Chairwoman of the Board | 7.58yrs | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Global Advisory Board | 1yr | no data | no data | |
| Independent Non-Executive Director | 1.5yrs | no data | no data | |
| Chairwoman of the Supervisory Committee | 2.17yrs | no data | no data | |
| Independent Non-executive Director | 1.5yrs | no data | no data | |
| Independent Non-Executive Director | 2.17yrs | no data | no data | |
| Shareholders Representative Supervisor | 2.17yrs | no data | no data | |
| Member of Global Advisory Board | 1yr | no data | no data |
2.2yrs
Average Tenure
55.5yo
Average Age
Experienced Board: 2500's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 2500 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.6%.
Top Shareholders
Company Information
Venus Medtech (Hangzhou) Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Venus Medtech (Hangzhou) Inc.
- Ticker: 2500
- Exchange: SEHK
- Founded: 2009
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: HK$38.342b
- Shares outstanding: 422.97m
- Website: https://www.venusmedtech.com
Number of Employees
Location
- Venus Medtech (Hangzhou) Inc.
- No. 88, Jiangling Road
- 3rd Floor
- Hangzhou
- Zhejiang Province
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 2500 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Dec 2019 |
| 2500 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Dec 2019 |
Biography
Venus Medtech (Hangzhou) Inc. develops and sells transcatheter heart valve medical devices in Mainland China and internationally. The company’s products include VenusA-Valve, a transcatheter aortic heart v...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/23 10:23 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.